Wednesday, July 8, 2026

Patent intelligence · US

US 12390512

Depolymerase capable of degrading extracellular polymeric substances of Klebsiella pneumoniae

granted A61KA61K31/43A61K38/47A61K45/06
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 19
Applicant portfolio 11
Patent details — US 12390512
Jurisdiction
US
Status
granted
Grant date
Aug 19, 2025
Expiration
Aug 14, 2045
Claims
20
CPC classes
A61K, A61K31/43, A61K38/47, A61K45/06
View on Google Patents ↗

Quick answer

US 12390512 (Depolymerase capable of degrading extracellular polymeric substances of Klebsiella pneumoniae) is held by SHANGHAI REINOVAX BIOLOGICS CO., LTD. Status: granted. Granted Aug 19, 2025. Expires Aug 14, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
20
CPC classes
A61K, A61K31/43, A61K38/47, A61K45/06, A61P, A61P31/04

More from SHANGHAI REINOVAX BIOLOGICS CO., LTD

Related pharmaceutical patents in our USPTO index.

  1. US 11033623

    Magnetic stem cell therapy for lesions

    GREINER BIO-ONE NORTH AMERICA, INC. · Expires Jun 10, 2041

    granted
  2. US 10472381

    Sialic acid derivatives

    Reinhard Brossmer · Expires Nov 7, 2039

    granted
  3. US 10265396

    Magnetic extracellular matrix

    GREINER BIO-ONE NORTH AMERICA, INC. · Expires Apr 18, 2039

    granted
  4. US 9539228

    Composition containing lysine as a nutritional supplement or treatment in the case of herpes

    Reiner Rittinghausen · Expires Jan 5, 2037

    granted
  5. US 8309071

    Foamy viral envelope genes

    Vectoria Forschungsforderungs Verein E.V. · Expires Nov 8, 2032

    granted
  6. US 8293803

    Retinoid compounds and their use

    Reinnervate Limited · Expires Oct 18, 2032

    granted
  7. US 8268792

    Use of an active ingredient combination that contains hydroxystilbene for preventing and/or treating diseases

    Reinhard Rettenberger · Expires Sep 13, 2032

    granted

Frequently asked questions

What is US patent 12390512?

US 12390512 (Depolymerase capable of degrading extracellular polymeric substances of Klebsiella pneumoniae) is held by SHANGHAI REINOVAX BIOLOGICS CO., LTD. Status: granted. Granted Aug 19, 2025. Expires Aug 14, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12390512?

SHANGHAI REINOVAX BIOLOGICS CO., LTD is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 11 pharmaceutical patents for this assignee.

When does US 12390512 expire?

Our index shows an expiration date of Aug 14, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.